UNSPSC 51332901: Bromerguride

This classification denotes a dopamine antagonist with the molecular formula C20H25BrN4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HX58M2377W, chemically known as 3-(2-bromo-9,10-didehydro-6-methylergolin-8alpha-yl)-1,1-diethylurea but generally known as bromerguride, which bears US NIH Compound Identifier 71266. European Medicines Agency schedules Bromerguride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05911MIG.

UNSPSC 51332901 Bromerguride is a Commodity code that shows minimal alignment with recent state and local procurement activity. The three opportunities posted under this code span naloxone and drug deactivation systems, therapeutic pharmacy initiatives, and generic pharmaceuticals — none of which directly correspond to bromerguride, a pharmaceutical agent with a narrow clinical indication. State and local procurement offices appear to be using this code imprecisely or defaulting to it for pharmaceutical-adjacent solicitations that do not match its intended scope.

The issuing bodies soliciting under the code include Seminole County, Florida (a county health department), the Texas Health and Human Services Commission (a state agency), and the Minnesota Multistate Cooperative Purchasing Alliance (a cooperative vehicle administered by the Minnesota Department of Administration). The Seminole County IFB (Solicitation IFB60459723LAS, due July 26, 2026) seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually for community health support; the Texas HHS Commission RFI (HHS0017013, posted April 3, 2026) is gathering vendor capabilities for direct-to-manufacturer prescription programs; and the MMCAP RFP (S1070000015802, due March 26, 2026) establishes multi-state contracts for generic pharmaceuticals and OTC products across state and local facilities in Minnesota, Oregon, and other participating jurisdictions. Activity concentrates in the Southeast (Florida) and Upper Midwest (Minnesota, Texas), with no indication of sustained, category-specific demand for bromerguride itself. The code does not reflect a coherent procurement market in state and local contracting right now — pursue only if your firm's bromerguride offerings align coincidentally with a future pharmaceutical procurement tagged to this code.